A comprehensive analysis and comparative study of the trends in thyroid cancer burden in China and globally from 1990 to 2021, with projections for the next 15 Years.
1/5 보강
[OBJECTIVE] This study aims to analyze the trends in incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of thyroid cancer across gender and age groups in China and globally f
APA
Yin Y, Zhang X (2025). A comprehensive analysis and comparative study of the trends in thyroid cancer burden in China and globally from 1990 to 2021, with projections for the next 15 Years.. Frontiers in oncology, 15, 1505728. https://doi.org/10.3389/fonc.2025.1505728
MLA
Yin Y, et al.. "A comprehensive analysis and comparative study of the trends in thyroid cancer burden in China and globally from 1990 to 2021, with projections for the next 15 Years.." Frontiers in oncology, vol. 15, 2025, pp. 1505728.
PMID
39980569 ↗
Abstract 한글 요약
[OBJECTIVE] This study aims to analyze the trends in incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of thyroid cancer across gender and age groups in China and globally from 1990 to 2021, using data from the Global Burden of Disease (GBD) database. Additionally, it projects the trends in thyroid cancer burden for the next 15 years for both China and the global population.
[MATERIALS AND METHODS] Thyroid cancer-related data were extracted from the 2021 GBD dataset. The average annual percentage change (AAPC) and the corresponding 95% confidence intervals (95% CI) were calculated using Joinpoint regression to reflect trends in the thyroid cancer burden. R software was used to perform a gender- and age-specific analysis and visualize the trends in thyroid cancer burden for both China and the global population. Furthermore, the Autoregressive Integrated Moving Average (ARIMA) model was employed to project the trends in thyroid cancer burden over the next 15 years.
[RESULTS] The results indicate a rising trend in the incidence and prevalence of thyroid cancer both in China and globally. Conversely, the mortality rate and DALYs show a declining trend over the same period. Age-specific analysis revealed that thyroid cancer is most prevalent among individuals aged 50-64. Gender-specific analysis indicated that the incidence rate is higher in females than in males. Projections for the next 15 years show that the age-standardized incidence rates for both males and females are expected to continue rising in China and globally. While the age-standardized mortality rate for females is projected to decline significantly, the mortality rate for males is predicted to stabilize.
[CONCLUSION] Between 1990 and 2021, the number of thyroid cancer cases has increased both in China and globally, while the mortality rate has shown a marked decline. This trend is expected to persist over the next 15 years. The growing population affected by thyroid cancer reflects a substantial disease burden, making thyroid cancer a significant global public health concern. The formulation of proactive and effective health policies is urgently needed.
[MATERIALS AND METHODS] Thyroid cancer-related data were extracted from the 2021 GBD dataset. The average annual percentage change (AAPC) and the corresponding 95% confidence intervals (95% CI) were calculated using Joinpoint regression to reflect trends in the thyroid cancer burden. R software was used to perform a gender- and age-specific analysis and visualize the trends in thyroid cancer burden for both China and the global population. Furthermore, the Autoregressive Integrated Moving Average (ARIMA) model was employed to project the trends in thyroid cancer burden over the next 15 years.
[RESULTS] The results indicate a rising trend in the incidence and prevalence of thyroid cancer both in China and globally. Conversely, the mortality rate and DALYs show a declining trend over the same period. Age-specific analysis revealed that thyroid cancer is most prevalent among individuals aged 50-64. Gender-specific analysis indicated that the incidence rate is higher in females than in males. Projections for the next 15 years show that the age-standardized incidence rates for both males and females are expected to continue rising in China and globally. While the age-standardized mortality rate for females is projected to decline significantly, the mortality rate for males is predicted to stabilize.
[CONCLUSION] Between 1990 and 2021, the number of thyroid cancer cases has increased both in China and globally, while the mortality rate has shown a marked decline. This trend is expected to persist over the next 15 years. The growing population affected by thyroid cancer reflects a substantial disease burden, making thyroid cancer a significant global public health concern. The formulation of proactive and effective health policies is urgently needed.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- CO transoral laser microsurgery for early glottic carcinoma with anterior commissure involvement.
- Reply: Persistent Racial Disparities in Lung Cancer Survival and the Overlooked Role of Post-Treatment Care.
- Gene Expression-Based Colorectal Cancer Prediction Using Machine Learning and SHAP Analysis.
- Racial/Ethnic Disparities in Non-Small Cell Lung Cancer Mortality in the U.S., 2000-2020: A Population-Based Study.
- Mechanistic study of deoxycholic acid in colorectal cancer based on network toxicology and machine learning approaches.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Generational trends in reproductive factors among women in the US: implications for breast cancer incidence.
- Assessing the global demand and supply of brachytherapy resources: a population-based observational study.
- Clinical Characteristics and Prognostic Prediction of Secondary Solid Malignancies in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
- Environmental endocrine disruptors and endometrial cancer: a systematic review of epidemiological studies.
- Prevalence and Outcomes of HER2-Low Versus HER2-0 Status in Patients with Metastatic Breast Cancer.